NASDAQ
Valion Bio, Inc. (VBIO)
♥ 531 Thanks from members
Valion Bio, Inc. (VBIO) faces severe going-concern risks, a severe cash depletion down to $2.1 million, and Nasdaq delisting pressures, counterbalanced by early-stage TLR5 pipeline advancement, recent 3i funding tranches, and shareholder approval for a 1-for-5 to 1-for-50 reverse stock split.